Viz.ai Proves AI is Still ‘Relevant’ in Medtech with $71M Financing

The financing would enable Viz.ai to expand its artificial intelligence platform beyond stroke and into areas of acute care such as cardiology, pulmonary, and trauma.

Omar Ford

March 17, 2021

2 Min Read
IMG_Mar172021at25520PM.jpg
Kaikoro -stock.adobe.com

Viz.ai has raised $71 million in a series C round to expand its artificial intelligence platform beyond stroke. Previously, the company raised $50 million in a series B round and has raised $150 million since inception.

The round was led by Scale Venture Partners and Insight Partners with participation from Greenoaks, Kleiner Perkins, Threshold Ventures, CRV, Innovation Endeavors, and Susa Ventures. 

Proceeds will bring Viz.ai’s Intelligent Care Coordination A.I. Platform into areas of acute care such as cardiology, pulmonary, and trauma. The financing will also allow the company to expand into new global markets.

"This latest round of funding validates the potential of Viz.ai’s technology, both in and beyond stroke care coordination," Chris Mansi, co-founder and CEO of Viz.ai, said in a release. "The investment will allow us to expedite our effort to bring the power of artificial intelligence and advanced mobile technology to prevent care breakdowns, improve patient outcomes and experience, and improve economics across the entire health system both in the United States and Europe."

The firm’s flagship product is Viz LVO. The technology uses advanced deep learning to communicate time-sensitive information about stroke patients straight to a specialist who can intervene and treat.

In a multi-center study using Viz LVO found a median time-to-notification of 5 minutes and 45 seconds across all of the sites involved when using the technology. In the study, containing the largest health AI data set to date, Viz LVO achieved 96% sensitivity and 94% specificity in identifying large vessel occlusions in 2,544 consecutive patients from 139 hospitals using scanners from multiple manufacturers.

The past few years have been fruitful for Viz.ai. MD+DI named Viz.ai as one of six AI Companies Set to Rock Medtech. And not only did the company secure a few nods from FDA – it was also involved in a collaboration with Medtronic.

About the Author

Omar Ford

Omar Ford is a veteran reporter in the field of medical technology and healthcare journalism. As Editor-in-Chief of MD+DI (Medical Device and Diagnostics Industry), a leading publication in the industry, Ford has established himself as an authoritative voice and a trusted source of information.

Ford, who has a bachelor's degree in print journalism from the University of South Carolina, has dedicated his career to reporting on the latest advancements and trends in the medical device and diagnostic sector.

During his tenure at MD+DI, Ford has covered a wide range of topics, including emerging medical technologies, regulatory developments, market trends, and the rise of artificial intelligence. He has interviewed influential leaders and key opinion leaders in the field, providing readers with valuable perspectives and expert analysis.

 

Sign up for the QMED & MD+DI Daily newsletter.

You May Also Like